Local view for "http://purl.org/linkedpolitics/eu/plenary/2003-03-27-Speech-4-009"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20030327.1.4-009"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
". – Mr President, I would like to congratulate Mr Caudron on his work. I very much welcome this initiative, which could be a real step forward in the battle against HIV/Aids, malaria and TB in the developing countries.
As has already been said, it is a rapidly growing problem, usually affecting the poorest and most vulnerable in society who have less access to health care and education – many of whom are women. In fact, they make up two thirds of the world's poor and bear the main burden of poverty. Therefore, the role of women as sufferers, main carers, educators and as active members of communities in the developing countries is key to finding the right solutions.
If we look at HIV/Aids, by the year 2000, 9 million women and 4.3 million children had died of Aids, and these figures are going up. In sub-Saharan Africa, 55% of HIV infected adults are women. Women face greater danger of HIV infection for biological and social reasons, because of lack of control of their sexual health and lack of access to preventative information.
So the focus of the opinion of the Women's Rights and Equal Opportunities Committee was on ensuring that drugs and treatment are affordable, that people in developing countries are central to the programmes and that the products developed and used in trials are suitable for local use. Simple practical matters such as how to store drugs safely and how to administer or take drugs are crucial. That is why grass-roots groups such as women's organisations must be fully involved in developing programmes and ensuring that training is given to health care providers in the use of products – whether in the home, the community or in institutions. Training, capacity-building and infrastructure must be developed to enable these clinical trials to be carried out effectively and to ensure the long-term success of this programme."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples